<unk>  is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. In the United States,<unk>  is indicated for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Tralokinumab
Bezlotoxumab
Ustekinumab
Evolocumab
Alirocumab
Olaratumab
Lanadelumab
Durvalumab